Vasovagal Syncope
16
5
7
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
19%
3 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (16)
Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates
The Effect of Water Carbonation on Orthostatic Tolerance
Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry
Mechanisms of Vasovagal Syncope
Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms.
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Study of Atomoxetine in the Prevention of Vasovagal Syncope
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
Essential Hypotension and Allostasis Registry
Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Observation of ImageReady™ MR Conditional Pacing System in China
Syncope Prediction Study
Relation Between Vasovagal Tendency and Smoking Among University Students
Cardioneuroablation for Neurocardiogenic Syncope
Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope
Hypnosis in Autonomic Function